Q-omics provides the consensus-scored MT-ND4L profile across patient tissues and cancer cell-line models. MT-ND4L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MT-ND4L is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MT-ND4L RNA expression shows 19,149 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where MT-ND4L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT-ND4L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT-ND4L survival associations across molecular data types. MT-ND4L RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT-ND4L RNA expression–survival associations across cancer types. High MT-ND4L expression shows unfavorable associations in KIRC, MESO and LUAD, but favorable associations in ACC, KICH and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MT-ND4L RNA expression.
This table summarizes MT-ND4L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MT-ND4L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT-ND4L shows lower tumor expression in KIRC, BRCA, LIHC, KIRP and CHOL and higher tumor expression in KICH. The KIRC box plot shows higher MT-ND4L RNA expression in normal versus tumor tissue (log2 FC = −0.572, t-test p < 0.001).
This table shows molecular features associated with MT-ND4L in patient tissues and cancer cell lines. In patient samples, MT-ND4L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MT-ND4L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and STOMACH.
